CGON News
Archived Headlines
- Bladder cancer biotech CG Oncology ups share offering by 44% ahead of $289 million IPO 01/23/24
- US IPO Week Ahead: January IPO market gets more large deals, led by health services firm BrightSpring 01/19/24
- Bladder cancer biotech CG Oncology sets terms for $201 million IPO 01/18/24
- US IPO Week Ahead: Short holiday week is primed for big launches 01/12/24
- Large filers bolster strong outlook for the 2024 IPO market 01/11/24
See more
Updated: Renaissance Capital's 1Q 2024 US IPO Market Review
US IPO Market's Green Shoots Take Root In the first quarter of 2024, the IPO market's green shoots grew further, with 30 IPOs raising a combined $7.8 billion. While deal count was in line with...read more
Renaissance Capital's January IPO Market Update
Eleven IPOs raised a combined $3.8 billion in January, the busiest month for both $100+ million and $1+ billion IPOs since late 2021. Six offerings raised $100 million or more, led by two billion-dollar deals: sports gear maker Amer Sports (AS)...read more
US IPO Weekly Recap: Biotech CG Oncology pops 96% in a 7 IPO week
Seven IPOs priced this past week, led by three that raised $100+ million. After upwardly revising the terms earlier in the week, CG Oncology (CGON) further upsized the offering and priced above the range to raise $380 million at a $1.3...read more
Bladder cancer biotech CG Oncology prices further upsized IPO above the range at $19
CG Oncology, a Phase 3 biotech developing an oncolytic immunotherapy for bladder cancer, raised $380 million by offering 20 million shares at $19, above the range of $16 to $18. The company offered 3 million more shares than anticipated. It originally planned to...read more